Digital Mammography Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Digital Mammography Market Trends and Insights

USPSTF Age-40 Screening Expansion Adds a Structural Volume Floor

In April 2024, the U.S. Preventive Services Task Force (USPSTF) extended biennial screening mammography to women aged 40 to 74, marking a significant shift in demand for the digital mammography market. Starting screenings at age 40 could save 20% more lives compared to the previous starting age of 50, with a larger benefit for Black women, who face a 40% higher mortality rate from breast cancer than White women.^{[1]U.S. Preventive Services Task Force, “Breast Cancer Screening,” U.S. Preventive Services Task Force, uspreventiveservicestaskforce.org} With a Grade B rating, employer health plans must provide first-dollar coverage, encouraging women in their 40s to undergo routine screenings under the Affordable Care Act. Younger screening cohorts, often with dense breast tissue, increase the operational value of Digital Breast Tomosynthesis (DBT) and AI-enhanced workflows, creating a stable volume floor for the market.

2-D to 3-D DBT Replacement Cycle Accelerates Across High-Income Markets

The digital mammography market is driven by an ongoing replacement cycle among 2-D full-field digital mammography systems. As of March 2025, 8,266 of 8,963 certified facilities in the United States had at least one accredited DBT unit, while 13,759 accredited 2-D units still slightly outnumbered 12,780 DBT units, highlighting significant upgrade potential.^{[2]U.S. Food and Drug Administration, “Important Information, Final Rule to Amend the Mammography Quality Standards Act,” U.S. Food and Drug Administration, fda.gov} DBT is increasingly preferred for organized screenings due to its ability to reduce recalls and improve reading efficiency. Vendors offering modular upgrades instead of full replacements are well-positioned, especially in public systems and community hospitals seeking modernization without overhauling capital plans.

Dense-Breast Notification and Follow-Up Imaging Push Drives Incremental Scan Volume

The digital mammography market gained momentum when MQSA-certified facilities in the United States were required from September 10, 2024, to notify patients about breast tissue density and its implications for cancer risk and mammographic sensitivity. Updated preventive services guidance for 2026 mandates coverage for additional imaging and pathology evaluations without cost-sharing when follow-up imaging is needed. This drives more women into advanced imaging pathways, often requiring DBT systems or supplemental imaging. With a significant portion of screening-age women in the United States having dense breasts, the market benefits from sustained demand for both primary screenings and higher-value follow-up exams.

AI-Enabled Throughput and Recall Reduction Redefines Radiologist Capacity

Artificial intelligence is transforming the digital mammography market by addressing throughput challenges amid radiologist shortages. A 2026 study showed AI-primary workflows increased cancer detection by 10.4%, reduced recall rates by 0.8%, and lowered radiologist workload by 37% to 44%. A 2025 study reported a 20.6% increase in breast cancer detection with AI-supported screening, with stable or improved recall rates.^{[3]M. Posso et al., “Prospective Evaluation of Artificial Intelligence Integration into Breast Cancer Screening in Multiple Workflow Settings, The GEMINI Study,” Nature Cancer, springer.com} Staffing shortages remain critical, with 70% of practices reporting insufficient mammography technologists in 2025. AI has become a key growth driver, enabling facilities to manage growing exam volumes while maintaining quality with limited staff.

Capital Budget Competition Slows Multi-Modality Upgrade Cycles

Despite favorable demand, the digital mammography market faces capital allocation challenges within health systems. Mammography platforms compete with CT, MRI, and PET/CT for limited budgets, a trend that has intensified since 2024 as providers manage debt, infrastructure upgrades, and service expansions. The high lifecycle costs of DBT platforms make procurement decisions reliant on reimbursement clarity and multi-year budgets rather than clinical preferences. Facilities in rural and emerging areas experience slower upgrades due to additional costs like room shielding, power stability, and PACS connectivity, which often exceed the scanner price. While demand remains strong, these factors extend replacement cycles and push upgrades into long-term planning.

Breast-Imaging Workforce Shortage Creates a Structural Capacity Ceiling

The digital mammography market is constrained by a shortage of radiologists and technologists, limiting its ability to meet rising screening and follow-up volumes. A 2025 Journal of Breast Imaging survey reported that 70% of practices were understaffed for mammography technologists. This staffing gap means improved eligibility and reimbursement do not always translate into increased capacity. Providers are increasingly adopting workflow software, triage tools, and integrated platforms to reduce manual workloads and maintain efficient reporting times. While demand is strong, uneven operating capacity slows the pace at which providers can capitalize on new opportunities.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: DBT Systems Take Share in a Digital Replacement Wave

In 2025, Digital Systems dominated the product-type revenue, claiming a substantial 60.45% share. This shift underscores the digital mammography market's decisive pivot away from its analog roots and retrofit-heavy configurations, especially in advanced imaging systems. Despite a significant installed base still featuring 2-D platforms, replacement demand remains robust in mature markets. C

3-D Breast Tomosynthesis Systems are on a rapid ascent, projected to grow at an 11.25% CAGR through 2031. Their momentum is bolstered by clinical validation, policy backing, and sound procurement rationale. As of March 2025, FDA data highlighted 12,780 accredited DBT units in the U.S., still trailing behind the 13,759 accredited 2-D digital units. This gap underscores the ongoing upgrade cycle. Facilities are increasingly drawn to DBT for its promise of fewer recalls and enhanced performance, especially in dense-breast demographics. 

By Technology: Photon-Counting Emerges as the Next Platform Shift

In 2025, 2-D Full-Field Digital Mammography accounted for a significant 50.9% of technology revenue, underscoring the continued reliance on legacy digital systems for near-term procedures. This stronghold is bolstered by a widespread installed base in community and rural facilities, coupled with the operational familiarity and reimbursement of 2-D procedures in various markets. Concurrently, AI-driven CAD and image triage are enhancing both 2-D and DBT hardware performance, allowing for improvements without immediate hardware upgrades. 

Photon-counting Digital Mammography is set to chart a robust trajectory, with projections indicating a 10.45% CAGR through 2031, marking it as the most rapidly advancing technology segment. Its allure lies in its detector architecture, which champions dose efficiency and spectral imaging. This ensures heightened sensitivity for detecting small invasive cancers and ductal carcinoma in situ, making it particularly relevant for younger screening demographics and sophisticated contrast workflows. Internationally, there's a burgeoning interest, with early installations and clinical applications in several European and Asian markets signaling a shift from mere trial-stage curiosity. 

By Application: Screening Dominates, Biopsy Guidance Accelerates

Screening, accounting for a commanding 72.35% of application revenue in 2025, solidified its status as the cornerstone of the digital mammography market. This dominance is anchored in statutory screening initiatives, payer-supported preventive care, and the fundamental role of screening as the gateway to most imaging pathways. The April 2024 USPSTF endorsement expanded the eligible screening demographic to encompass women aged 40 to 74, bolstering the trajectory of routine screening demand. 

Interventional and Biopsy Guidance is witnessing the swiftest growth, with projections indicating a 10.78% CAGR through 2031. This surge is attributed to a growing preference among facilities to consolidate detection and tissue confirmation within a single visit. Such a shift aligns with care models aimed at minimizing delays, enhancing patient retention, and maximizing value for outpatient and specialty breast centers. 

By End User: Ambulatory Channels Gain Ground on Hospital Anchors

In 2025, hospitals commanded a notable 44.67% of end-user revenue, solidifying their position as the primary procurement channel in the digital mammography landscape. Their dominance is attributed to the necessity of lead-lined rooms, integrated PACS, specialized personnel, and the capability to navigate diagnostic complexities, biopsies, and high-acuity imaging services. 

Diagnostic Imaging Centers are emerging as the fastest-growing segment, with an impressive projected growth rate of 11.55% CAGR through 2031. Their ascent in the digital mammography arena is largely due to payer preferences shifting towards more economical outpatient care venues. These centers excel in high-throughput screening, AI-assisted readings, and adaptable scheduling, enabling them to efficiently manage routine demands—often outpacing many hospital departments. Moreover, specialty breast centers and office-based models are gravitating towards same-day service offerings. 

Geography Analysis

North America accounted for 61.11% of global revenue in 2025, driven by robust federal funding. North America holds the largest share of the digital mammography market, driven by well‑established breast cancer screening programs, strong reimbursement frameworks, and rapid adoption of advanced technologies like 3D tomosynthesis and AI‑assisted diagnostics. The U.S., in particular, benefits from FDA approvals and insurance coverage that encourage hospitals and imaging centers to upgrade from analog to digital systems. High awareness levels and government initiatives further reinforce market dominance, though equipment costs remain a challenge for smaller clinics.

Europe represents a mature market with widespread adoption supported by national screening programs in countries such as Germany, France, and the UK. The region emphasizes early detection and quality standards, with structured reimbursement policies ensuring accessibility. 

The Middle East is an emerging market for digital mammography, with countries like Saudi Arabia and the UAE investing heavily in modern diagnostic infrastructure. Growth is fueled by rising breast cancer incidence, government‑backed awareness campaigns, and partnerships with international healthcare providers.